Author

N. J. Curtin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 1

Frequent Co-Authors

H. L. Smith· 2 shared A. Mukhopadhyay· 1 shared E. J. Willmore· 1 shared E. Willmore· 1 shared L. Prendergast· 1 shared Y. Drew· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

6 top collaborators · 9 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

H. L. Smith

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Overcoming PARP inhibitor resistance by inducing a homologous recombination repair defective phenotype with ATR, CHK1 and WEE1 inhibitors

H. L. Smith, E. Willmore, L. Prendergast, N. J. Curtin

This paper shows that ATR, CHK1, and WEE1 inhibitors induce an HRD phenotype, making cells sensitive to PARP inhibitors.

bioRxiv · Jul 5, 2023 · PreprintCancer Biology

Differences in durability of PARP inhibition by clinically approved PARP inhibitors: implications for combinations and scheduling

H. L. Smith, E. J. Willmore, A. Mukhopadhyay, Y. Drew, N. J. Curtin

This paper compares the durability of PARP inhibition by five PARP inhibitors in ovarian cancer cells and shows rucaparib provides the longest-lasting inhibition, with implications for combination therapies with ATR inhibitors.

bioRxiv · Jan 24, 2022Pharmacology & Toxicology